On March 27, 2026, OnKure Therapeutics, Inc. announced that it has entered into a securities purchase agreement with institutional accredited investors, raising approximately $150 million through the issuance of 26,713,636 shares of its Class A common stock at a price of $4.15 per share, along with pre-funded warrants to purchase an additional 9,430,959 shares at an exercise price of $4.1499 per share. The private placement is expected to close on March 31, 2026, subject to customary closing conditions. The funds raised will be utilized to support the preclinical and clinical development of OnKure's next-generation PI3Kα pan-mutant-selective inhibitor candidates, specifically targeting breast cancer and vascular anomalies, as well as for general corporate purposes. Leerink Partners LLC is acting as the lead placement agent, with Evercore Group L.L.C., LifeSci Capital LLC, and Oppenheimer & Co. Inc. serving as co-placement agents. The agreement includes customary representations and warranties, and the company’s executive officers and directors have agreed not to sell or transfer any common stock for 180 days following the closing date. Additionally, the lead investor has the right to designate a nominee to the company's board of directors, contingent upon maintaining a significant ownership stake in the securities purchased. This strategic financing is expected to enhance OnKure's operational capabilities and accelerate its clinical development pipeline, positioning the company for future growth in the oncology sector.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.